<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03118570</url>
  </required_header>
  <id_info>
    <org_study_id>MBPS205</org_study_id>
    <secondary_id>2016-005096-27</secondary_id>
    <nct_id>NCT03118570</nct_id>
  </id_info>
  <brief_title>A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804</brief_title>
  <acronym>ASTEROID</acronym>
  <official_title>A Phase 2b Study, Multicentre, Multinational, Placebo-controlled, Double-blind, Dose-finding Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mereo BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICON Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mereo BioPharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to select a suitable dose of BPS804 by comparing it with a dummy
      treatment and measuring the strength/quality of bone using a special type of CT scanner.
      Participants will be treated for 1 year.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 11, 2017</start_date>
  <completion_date type="Anticipated">May 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Placebo-controlled, Double-blind, Dose-finding Study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Sponsor will be masked until the primary analysis of the study. The study site pharmacist will be unmasked to treatment allocation throughout. Study treatment will be monitored by a separate unmasked monitoring team.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Trabecular Volumetric Bone Mineral Density (mgHA/cm3)</measure>
    <time_frame>6 months</time_frame>
    <description>High Resolution Peripheral Quantitative Computated Tomography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in bone strength on Finite Element Analysis (N)</measure>
    <time_frame>6 months</time_frame>
    <description>High Resolution Peripheral Quantitative Computated Tomography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Trabecular Volumetric Bone Mineral Density (mgHA/cm3)</measure>
    <time_frame>12 months</time_frame>
    <description>High Resolution Peripheral Quantitative Computative Tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bone strength on Finite Element Analysis (N)</measure>
    <time_frame>12 months</time_frame>
    <description>High Resolution Peripheral Quantitative Computative Tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life Patient Reported Outcome Scores (total &amp; sub-domains)</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>OI-QOL-A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life Patient Reported Outcome Scores (total &amp; sub-domains)</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>SF-12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life Patient Reported Outcome Scores (total &amp; sub-domains)</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>EQ5D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in lumbar bone mineral density (t-score)</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Dual-energy x-ray absorptiometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in whole body bone mineral density (t-score)</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Dual-energy x-ray absorptiometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in proximal femur bone mineral density (t-score)</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Dual-energy x-ray absorptiometry</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum concentrations of BPS804, anti-BPS804 antibodies and BPS804 neutralising antibodies</measure>
    <time_frame>12 months</time_frame>
    <description>Serum concentrations of BPS804, anti-BPS804 antibodies and BPS804 neutralising antibodies</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Osteogenesis Imperfecta, Type I</condition>
  <condition>Osteogenesis Imperfecta Type III</condition>
  <condition>Osteogenesis Imperfecta Type IV</condition>
  <arm_group>
    <arm_group_label>BPS804 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BPS804 IV Infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BPS804 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BPS804 IV Infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BPS804 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BPS804 IV Infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - 5% Dextrose IV Infusion</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>5% Dextrose IV Infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BPS804</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>BPS804 Dose 1</arm_group_label>
    <arm_group_label>BPS804 Dose 2</arm_group_label>
    <arm_group_label>BPS804 Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo IV Infusion 5% Dextrose</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>Placebo - 5% Dextrose IV Infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a clinical diagnosis of OI Type I, III or IV with a confirmed defect in
             the COL1A1/COL1A2 genes, as confirmed by genetic testing

          -  One or more fractures in the past 24 months

          -  Capable of giving signed consent

        Exclusion Criteria:

          -  History of skeletal malignancies or other bone diseases (other than OI)

          -  History of endocrine or thyroid/parathyroid conditions that could affect bone
             metabolism

          -  Treatment with bisphosphonates within 3 months of randomisation

          -  Treatment with teraparatide, denosomab or other anabolic/antiresorbative medications
             within 6 months of randomisation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jay Shapiro, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francis Glorieux, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shriner's Hospital for Children, Montreal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kassim Javaid, Assoc. Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nuffield Orthopaedic Centre, University of Oxford Hospitals Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ian Hodgson, PhD</last_name>
    <phone>+44 3330237300</phone>
    <email>enquiries@mereobiopharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anthony Hall, MB BS BSc</last_name>
    <phone>+44 3330237300</phone>
    <email>enquiries@mereobiopharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>012115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ian Hodgson</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Paris</city>
        <state>Paris Cedex 14</state>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <state>Newcastle</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Hodgson, PhD</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.asteroidstudy.com</url>
    <description>Study Website</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2017</study_first_submitted>
  <study_first_submitted_qc>April 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2017</study_first_posted>
  <last_update_submitted>February 2, 2018</last_update_submitted>
  <last_update_submitted_qc>February 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteogenesis Imperfecta</keyword>
  <keyword>Brittle Bone Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteogenesis Imperfecta</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

